Tiny blood test could predict deadly sepsis in preterm infants

NCT ID NCT03291496

Ongoing Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new microfluidic device that uses a very small blood sample to measure how well immune cells (neutrophils) function in premature newborns. The goal is to see if this test can predict which babies will develop sepsis, a life-threatening infection. Researchers will collect blood from 293 preterm and term infants, as well as healthy adults, to compare results and identify early warning signs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that predicts sepsis in premature babies before symptoms appear, potentially saving lives and reducing long-term health problems.
What could go wrong: This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all hospitals or newborn populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neonatal sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEONATAL SEPSIS

Contacts and locations

Locations

UF Health

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.